Rosetta Genomics' Cancer Origin Test Highlighted on The Dr. Steve Show

Rosetta Genomics' Cancer Origin Test Highlighted on The Dr. Steve Show 
Patient Story Underscores the Need for Accurate Diagnosis of Tumor
Origin as the First Ever Cancer of Unknown Primary Awareness Week
Launches 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 09/23/13 --  
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces that the
Rosetta Cancer Origin Test(TM) will be featured in an upcoming
episode on The Dr. Steve Show, a nationally syndicated 30-minute
health, well-being and lifestyle program. The segment is expected to
air the first weekend in October 2013 in the following markets: 
New York 
 PIX11 
 Sun 6:30PM 
Philadelphia 
 PHL17 
 Sat 12:30PM 
Houston 
 KIAH 
 Sun 9:00AM 
Separately, the Company congratulates the Cancer of Unknown Primary
(CUP) Foundation's launch of the first annual "CUP Awareness Week"
taking place from September 23-29, 2013, which is expected to raise
awareness for this little known diagnostic dilemma. "We applaud the
efforts of the CUP Foundation in providing valuable information and
support to CUP patients and their families," said E. Robert Wassman,
MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer. "The
reality is that a diagnosis of CUP is not a diagnosis at all, and can
lead to increased patient anxiety and frustration with their care, as
illustrated in our patient story highlighted on the Dr. Steve Show.
With new advances in molecular diagnostics such as the Cancer Origin
Test, an unknown or uncertain diagnosis is unacceptable."  
The episode features "Bernard's Story," a chronicle of this patient's
compelling journey commencing with a Cancer of Unknown Primary
diagnosis and the frustrations and difficulties associated with not
knowing his cancer's tissue of origin. The story then moves forward
with the cancer's origin being identified through the use of Rosetta
Genomics Cancer Origin Test, and the patient's subsequent clinical
and emotional benefits associated with having this critical
knowledge. 
"This feature brings to life the critical need to know the tumor of
origin in order to guide treatment decisions and patient outcomes,"
stated Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics. "Developments in targeted cancer therapies are
driving the need for more accurate classification of tumor types,
which help to guide treatment decisions. Our microRNA technologies,
with their high reproducibility, robustness, and accuracy are well
suited to provide valuable clinical information to predict and
diagnose cancer, and therefore, help to optimize treatment as
illustrated in this patient's story."  
About the Dr. Steve Show
 Dr. Steve is a 30-minute health, wellness
and lifestyle program. The multi-topic show is hosted by Dr. Steve
Salvatore, a board certified Emergency Medicine physician who has
served as the health expert on PIX11 Morning News since 2005. Dr.
Steve features a mix of wellness topics including fitness and
nutrition experts, kitchen nutrition makeovers, gadget and product
reviews, children's health and topical parenting issues. Dr. Steve
also features everyday heroes, profiles of ordinary people with
extraordinary stories. 
About Rosetta Cancer Testing Services Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). The Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and the benign
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone,
Rosetta Genomics estimates that 200,000 patients a year may benefit
from the Cancer Origin Test, 60,000 from the Mesothelioma Test,
65,000 from the Kidney Cancer Test and 226,000 patients from the Lung
Cancer Test. The Company's assays are offered directly by Rosetta
Genomics in the U.S., and through distributors around the world. For
more information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215)
382-9000 ext. 309. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test, the Cancer Origin Test improving the ability of physicians to
accurately diagnose CUP, the Cancer Origin Test's ability to help
physicians to optimize treatment, Rosetta's development or
commercialization of molecular diagnostics, the market acceptance of
Rosetta's cancer testing services, particularly the Cancer Origin
Test, the featuring of Rosetta Genomics and/or the Cancer Origin Test
in the Dr. Steve Show, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a result
of various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta's Annual Report on
Form 20-F for the year ended December 31, 2012 as filed with the SEC.
In addition, any forward-looking statements represent Rosetta's views
only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless
required by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin 
President & CEO 
(609) 419-9000, ext. 1326 
investors@rosettagenomics.com 
Investor Contacts: 
LHA 
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com